Last reviewed · How we verify

NCT05590546

Sympathetic Transduction in Obesity

Not yet recruiting Last updated 3 October 2024
What this trial tests

trial testing No intervention in Hypertension in 28 participants. Not yet recruiting.

Timeline
1 October 2025
Primary endpoint
19 November 2026
19 December 2026

Quick facts

Lead sponsorUniversity of Kansas Medical Center
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment28
Start date1 October 2025
Primary completion19 November 2026
Estimated completion19 December 2026

Drugs / interventions tested

Conditions studied

Sponsor

University of Kansas Medical Center

Who can join

Adults 35 to 65, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Central (abdominal) obesity is associated with elevated adrenergic activity and arterial blood pressure (BP). Therefore, we tested the hypothesis that transduction of spontaneous muscle sympathetic nerve activity (MSNA) to BP, i.e., sympathetic transduction, is augmented in abdominal obesity (increased waist circumference) and positively related to prevailing BP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other University of Kansas Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05590546.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing